马来酸曲美布汀联合复方消化酶胶囊治疗便秘型肠易激综合征

目的 观察马来酸曲美布汀联合复方消化酶胶囊治疗便秘型肠易激综合征的临床疗效及安全性.方法 将符合罗马Ⅲ标准的138例便秘型肠易激综合征患者随机分为治疗组72例和对照组66例.治疗组用马来酸曲美布汀片200mg/次,3次/d,复方消化酶胶囊2粒/次,3次/d;对照组单用马来酸曲美布汀片200mg/次,3次/d,疗程均为4周.结果 4周后两组腹痛、腹胀均有明显改善.治疗组腹痛、腹胀缓解总有效率分别为97.2％、98.6％.对照组腹痛、腹胀缓解总有效率分别为84.8％、87.8％.两组Bristol粪便性状分型均明显改善,治疗组对腹痛、腹胀及便秘的改善比对照组更为明显,差异有统计学意义（P＜0.05）.两组不良反应的差异无统计学意义.结论 马来酸曲美布汀联合复方消化酶胶囊可有效治疗便秘型肠易激综合征,且安全性高,值得临床推广应用.

Trimebutine Maleate Tablets combined with compound Digestive Enzyme on the Treatment of Constipation-predominant Irritable Bowel Syndrome

Objective To evaluate the efficacy and safety of teimebutine Meleate tablets combined with compound Di- gestive Enzyme on the treatment of constipation-predominant Irritable Bowel Syndrome. Methods In a randomized controlled experiment, one hundred thirty-eight cases with constipation predominant irritable bowel syndrome were randomly divided into two groups. Patients in both groups received trimebutine Maleate tablets treatment. The cases in the test group（72 cases） re- ceived an additional compound Digestive Enzyme treatment. The duration of treatment was four weeks. Results After treat- ment, the total symptom scores of two groups all were obviously decreased. The total efficacy rate of abdominal pain and full- ness were 84.8%, 87.8% in the control group, which was significantly lower than those in the test group （97%, 98.6%, P 〈 0.05 ）. The type of stool in two groups showed significant improvement comparing with baseline （ P 〈 0. 05 ）. The adverse e- vent in two groups showed no significant difference （P 〉 0. 05）. Conclusion The treatment scheme of trimebutine maleate tab- lets with compound digestive enzyme for treatment of constipation-preadominant irritable bowel syndrome is safe and effective, which is worthy of popularization and application.